Alpha Cognition Inc. Common Stock (ACOG) has a MoatMap StockRank of 24/100 based on Quality (29/100), Value (38/100), and Momentum (44/100) factor scores. The current signal is SELL. Alpha Cognition is a microcap biopharmaceutical company focused on neurodegenerative diseases. It is highly speculative, unprofitable, and lacks the established commercial moat and high ROIC required by our investment philosophy.
Alpha Cognition Inc. is a biopharmaceutical company focused on developing novel diagnostic and therapeutic agents for neurodegenerative diseases, particularly Alzheimer's and ALS. It advances a proprietary diagnostic and therapeutic platform targeting specific biomarkers, aiming to provide earlier detection and more effective treatments for challenging neurological conditions. The company is a clinical-stage biotechnology firm specializing in neurodegenerative disorders, addressing significant unmet medical needs through innovative approaches.
| Price | $6.18 |
| Market Cap | $129M |
| P/E (Forward) | -11.88 |
| Price/Book | 2.23 |
| Return on Equity | -51.7% |
| Return on Invested Capital | -32.0% |
| Gross Margin | 87.5% |
| Operating Margin | -229.1% |
| Revenue Growth | 20.7% |
| Free Cash Flow | $-21M |
Alpha Cognition Inc. Common Stock operates in the Biotechnology industry, part of the Healthcare sector (United States).